logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Arlington Capital Partners Announces The Acquisition Of Avs Bio

Jan 05, 2023•almost 3 years ago

Acquiring Company

Arlington Capital Partners

Acquired Company

AVS Bio

WashingtonVenture CapitalBiotechnologyHealth CareManufacturing

Description

Arlington Capital Partners (“Arlington”), a Washington, DC-area private equity firm, announced today it has acquired Charles River Laboratories’ (NYSE:CRL) Avian Vaccine Services business to form a new company, AVS Bio (the “Company”). The Company will operate independently as a standalone platform for Arlington that will serve the biologic manufacturing and bioprocessing markets.

Company Information

Company

Arlington Capital Partners

Location

Washington, District Of Columbia, United States

About

Arlington Capital Partners is a Washington, DC-based private equity firm that is currently investing out of Arlington Capital Partners V, L.P., a $1.7 billion fund. The firm has managed approximately $4.0 billion of committed capital via five investment funds. Arlington is focused on middle market investment opportunities in growth industries including government services and technology, aerospace & defense, healthcare, and business services and software. The firm’s professionals and network have a unique combination of operating and private equity experience that enable Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and/or advance their Company’s position as leading competitors in their field. www.arlingtoncap.com

Related People

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed